Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen has avoided an interruption in US supply of Increlex (IGF-1) to treat Severe Primary IGF-1 Deficiency due to delays in manufacturing site approval.
Subscribe to our email newsletter
Ipsen has worked in close relation with the US Food and Drug Administration to maintain product supply as the product is a medical necessity.
Increlex’s active principle, IGF-1 is manufactured by Lonza Biologics at its Hopkinton facility, US.
The companies will work with FDA to supply Increlex to US patients, according to Ispen.
Increlex is prescribed to children who are very short for their age as their bodies do not make enough IGF-1.